Sunny Pharmtech

Sunny Pharmtech EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is -159.64 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -59.70 M TWD — a change of 167.41% (lower).

EBITDA

-159.64 MTWD

YoY

167.41%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunny Pharmtech is 2024 -159.64 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunny Pharmtech was 2023 -59.70 M TWD. It decreases by 167.41% lower compared to the previous year.

The Sunny Pharmtech EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-299.00 M TWD
Jan 1, 2019
-214.04 M TWD
Jan 1, 2020
-74.34 M TWD
Jan 1, 2021
-176.00 M TWD
Jan 1, 2022
-187.62 M TWD
Jan 1, 2023
-59.70 M TWD
Jan 1, 2024
-159.64 M TWD
The Sunny Pharmtech EBITDA history
YEAREBITDAYoY
-159.64 MTWD+167.41%
-59.70 MTWD-68.18%
-187.62 MTWD+6.60%
-176.00 MTWD+136.75%
-74.34 MTWD-65.27%
-214.04 MTWD-28.41%
-299.00 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunny Pharmtech is -159.64 M TWD in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunny Pharmtech changed from -59.70 M TWD to -159.64 M TWD, representing a 167.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sunny Pharmtech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech